Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

This live, virtual symposium will bring together a world-renowned expert in the management of breast cancer with a local community oncologist to discuss the role of next-generation selective estrogen receptor degraders (SERDs) in the treatment of hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer.
Learn More